Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,252 matching trials from the live ClinicalTrials.gov search.
Conditions
NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions
TS-104
Drug
Lead sponsor
TwoStep Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Maumee, Ohio • Portland, Oregon • Fairfax, Virginia
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography, Computed Tomography, Electronic Health Record Review
Biological · Drug · Procedure + 1 more
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Petosemtamab, Pembrolizumab
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
36
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more
Completed Phase 1Phase 2 Interventional Results available

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196
Conditions
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
NKTR-255, Cetuximab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more
Conditions
HNSCC
Interventions
eftilagimod alpha, pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Immutep S.A.S.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Remediation of Impaired Self-Regulation in Patients With Mild TBI

NCT02260570
Conditions
Mild Traumatic Brain Injury
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Sacramento, California
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers

Ensuring Communication in Hospice by Oncology Study (ECHO)

NCT02069769
Conditions
Ovarian Cancer, Cervical Cancer, Uterine Cancer, Head and Neck Cancer, Sarcoma, Melanoma
Interventions
communication with oncology team
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Radiation Exposure
Interventions
Standard PPE, Texray PPE
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Conditions
Tongue Tumor, Tongue Cancer
Interventions
CT Scan, Experimental Oral Stent Device
Diagnostic Test · Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Squamous Cell Carcinoma, Oral Cancer
Interventions
Docetaxel, Cisplatin, 5-fluorouracil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Head and Neck Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Barrett's Esophagus With High Grade Dsyplasia, Early Esophageal Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 58 more
Conditions
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
Interventions
Itraconazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Palo Alto, California • Ann Arbor, Michigan • Durham, North Carolina + 4 more
Conditions
Trauma
Interventions
Workshop
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Head and Neck Cancer
Interventions
PET/CT Imaging
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Head and Neck Cancer
Interventions
A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Avelumab, Chemoradiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
139
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more
Conditions
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
Interventions
Nivolumab Injection, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Robert L. Ferris, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Portland, Oregon • Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Postural Education or Corrective Exercise on Forward Head Posture

NCT05321654
Conditions
Postural; Defect
Interventions
Education for Behavior Modification, Corrective Exercise Program
Behavioral
Lead sponsor
Liberty University
Other
Eligibility
18 Years to 29 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lynchburg, Virginia
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Genetic Disease Investigators
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Colleyville, Texas
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
brentuximab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 57 more